The 670G actually uses data from the sensor to give you insulin. This is an enormous step toward a genuine closed loop/artificial pancreas system, and is a really big deal.
Category: Artificial Pancreas
Medtronic announced on June 27 that it has submitted its Hybrid Closed Loop System (otherwise known as the MMT-670G system) to the FDA for approval. While not technically an artificial pancreas, the system consists of two parts: an insulin pump and a continuous glucose monitor. Once the system has been calibrated, the pump uses the readings from the CGM (which are taken every five minutes) to deliver insulin, with the goal of keeping blood sugars within a target range.
Type Zero Technologies' chief mathematician, Dr. Boris Kovatchev, reached out to Riding on Insulin to gauge interest in being part of a groundbreaking artificial pancreas trial.
Bigfoot’s goal is to make pump-sensor therapy simpler than the pump companies before them have. They envision themselves as a service provider rather than a hardware or device company. Their service will be to “do a better job delivering insulin,” automating your between-meal insulin therapy, the communication between your pump and your Dexcom CGM, even so far as serving as a single point of contact for all of your supply and prescription inventory management, sending you supplies when you need them, “connecting everything, making it intuitive,” says Brewer.
While we will not see a true artificial pancreas - a closed-loop insulin pump and continuous glucose monitoring system - come to market in 2016, we are so close we can artificially taste it.
We are excited to learn that based on the ten years of clinical trials at UVA, a new startup, Type Zero, is taking the inControl Diabetes Management Platform -- which is the software running the UVA AP -- to the next level.
Medtronic, Inc. announced the global launch of the MiniMed 640G System, the next breakthrough toward an artificial pancreas.
The system is the first in the world to both automatically suspend insulin delivery when sensor glucose levels are predicted to approach a low limit, and then resume insulin delivery once sensor glucose levels recover.
Medtronic has begun enrolling patients in an investigational device exemption (IDE) study of its new and innovative Predictive Low Glucose Management (PLGM) technology. The start of this study marks a critical step toward development of an artificial pancreas in the U.S. market.
In anticipation of stable, liquid glucagon, one of the newest entrants into the insulin pump space, Tandem Diabetes Care has jumped ahead of the crowd and created a two-chamber infusion pump capable of holding and injecting both insulin and a secondary hormone, which they expect will be glucagon. This tandem Tandem pump is already being tested in Dr. Ed Damiano's clinical trial of a dual-hormone bionic pancreas.
JDRF has announced a two partnerships to support the development soluble glucagon formulations—an important step toward the advancement of future generation, fully automated and multi-hormonal artificial pancreas systems for people with type 1 diabetes (T1D).